CN114470133B - 一种抗心因性肌肉震颤的组合物 - Google Patents

一种抗心因性肌肉震颤的组合物 Download PDF

Info

Publication number
CN114470133B
CN114470133B CN202210091750.9A CN202210091750A CN114470133B CN 114470133 B CN114470133 B CN 114470133B CN 202210091750 A CN202210091750 A CN 202210091750A CN 114470133 B CN114470133 B CN 114470133B
Authority
CN
China
Prior art keywords
parts
muscle
tremor
psychogenic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210091750.9A
Other languages
English (en)
Other versions
CN114470133A (zh
Inventor
苗莉
陈永进
张旻
黄飞
姜维
赵美
李晰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Air Force Medical University of PLA
Original Assignee
Air Force Medical University of PLA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Air Force Medical University of PLA filed Critical Air Force Medical University of PLA
Priority to CN202210091750.9A priority Critical patent/CN114470133B/zh
Publication of CN114470133A publication Critical patent/CN114470133A/zh
Application granted granted Critical
Publication of CN114470133B publication Critical patent/CN114470133B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/234Cnidium (snowparsley)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534Mentha (mint)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704Polygonum, e.g. knotweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

本发明涉及药物、保健品和食品技术领域,具体涉及一种抗心因性肌肉震颤的组合物,其由如下重量份的原料制成:姜黄1‑35份、虎杖1‑35、薄荷1‑35份、蛇床子1‑35份、鹿衔草1‑35份、苏木1‑35份、降香1‑35份、旋复花1‑35份、可可脂1‑50份。本发明具有拮抗心因性肌肉神经异常兴奋、降低肌肉张力、抑制肌肉的不自主运动,起到抗肌肉震颤的效果,而且对正常神经无抑制作用,不会引起肌肉的松弛,可以有效降低肌肉能耗,减少肌肉持续震颤引起的肌肉拉伤、肌肉疼痛和肌肉间质的炎性增生。

Description

一种抗心因性肌肉震颤的组合物
技术领域
本发明涉及药物、保健品和食品技术领域,具体涉及一种抗心因性肌肉震颤的组合物。
背景技术
肌肉震颤是指身体某一部分不自主的、或有节律的运动,对自主运动造成严重影响,是关于机体肌肉群收缩的功能性病变。肌肉震颤是造成肌肉拉伤、肌肉疼痛重要诱因,但由于肌肉震颤没有明确的病理变化基础,导致其在诊断和治疗都很困难,临床以心因性震颤为最常见的形式。
心因性肌肉震颤发病机制复杂,多由人的心理压力、情绪情感的剧烈波动或心理应激所导致。据统计,心因性起源的神经内科疾病诊断的约占1%~9%,其中以心因性肌肉震颤的发生率高居首位。心因性肌肉震颤可发生于任何年龄阶段,不受季节限制,表现为局部或多处肌肉的震颤,肌肉不自主运动,以肌肉的异常收缩,或主动肌与拮抗肌交替收缩,也可引起与肌肉相关联的关节出现不自主的、或快速节律性运动。这种震颤可有一定方向,震幅大小不一,以手部最常见,其次为眼睑、头和口舌部肌肉。震颤发生在四肢和手指肌肉群,则极大地影响精细工作的精确度和正常生活,发生在口颌系统则表现为咀嚼肌震颤和舌的肌肉张力增加,对正常咀嚼、发声和语言表达能力造成严重干扰,造成人的情绪和心理的挫败感,加重患者较大的生理困扰和心理压力,形成恶性循环。
肌肉运动受肌肉神经兴奋性支配,发生心身应激反应后体内促肾上腺皮质激素(ACTH)和皮质酮(CORT)升高,引起神经系统处于高度兴奋水平,造成控制肌肉运动的传出神经异常兴奋,肌肉张力增加。虽然神经和肌肉的高兴奋性可以提高肌肉的运动能力,但也打破了神经和肌肉的静息和兴奋的动态平衡状态,如果中枢的抗应激兴奋性不能迅速降低,则会导致肌肉的不自主运动增加,出现肌肉震颤,即形成心因性肌肉震颤,如果此时机体进行较为剧烈的运动,在多重神经信号强烈的刺激下,各组肌肉群间的协同性降低,则极易造成肌肉拉伤。另一方面,长时间的肌肉震颤会提高肌肉能耗,过度激活线粒体的氧化还原反应,造成线粒体的氧化损伤,引起肌肉的炎性反应,长期肌肉损伤会导致间质增生或肌肉筋膜炎,产生肌肉和关节疼痛。
目前关于治疗心因性肌肉震颤药物的研究极少,临床针对较严重的肌肉震颤多采用镇静神经类药物、抗焦虑抑郁药,或抗肌肉痉挛的肌松药,降低神经和肌肉兴奋性,而此类药物不仅属于管制类处方药,诊断和使用的流程复杂,却副作用也极显著,不能忽视。
中医理论中没有直接关于心因性肌肉震颤的病因病机阐述,仅在平肝熄风类方剂的适应症中有关于眩晕欲仆,头痛如掣,肢麻震颤,手足蠕动,语言不利,步履不稳等描述,但与心因性肌肉震颤的病因病机并不相同。平肝熄风类方剂以天麻钩藤饮、镇肝熄风汤等为代表,涉及药物多以重镇安神和平肝熄风药为主,药性猛烈,毒副作用较大。因此,寻找对证治疗、疗效显著、毒副作用少的药物是解决这些问题的关键。
发明内容
本发明提供一种抗心因性肌肉震颤的组合物,该组合物具有拮抗心因性肌肉神经异常兴奋、降低肌肉张力、抑制肌肉的不自主运动,起到抗肌肉震颤的效果。
为了达到上述目的,本发明提供如下技术方案:一种抗心因性肌肉震颤的组合物,由如下重量份的原料制成:姜黄1-35份、虎杖1-35、薄荷1-35份、蛇床子1-35份、鹿衔草1-35份、苏木1-35份、降香1-35份、旋复花1-35份、可可脂1-50份。
优选的,姜黄12份、虎杖20份、薄荷18份、蛇床子30、鹿衔草30份、苏木18份、降香18份、旋复花35份、可可脂50份。
本发明还提供了一种可用于心因性肌肉震颤的中药组合物的制备方法,包括如下步骤:
步骤S1,取配方份的姜黄、虎杖、鹿衔草、旋复花用乙醇回流提取,减压浓缩至2g生药/mL,喷雾干燥;
步骤S2,蛇床子、降香、薄荷,苏木十倍水溶剂下水蒸气蒸馏8小时制备精油;
步骤S3,将可可脂在50℃水浴下融化,与精油充分混合,水浴涡旋条件下逐量加入喷雾干燥粉末,冰水浴中静置冷却即得制剂。
进一步,步骤S1中的乙醇浓度均为45%.
本发明有益效果为:
1、本发明可显著抑制心理应激反应引起的神经过度兴奋性,降低静息状态下肌肉的张力、缓解神经和肌肉紧张,达到抑制肌肉震颤的效果;
2、本发明可显著降低血液中促肾上腺素和肾上腺素皮质酮的水平,降低肌肉兴奋性,抑制肌肉线粒体和内质网的氧化反应,抑制肌肉间质水肿,防止肌肉震颤损伤;
3、本发明可显著促进肌肉组织血管的舒张,改善心理应激引起的血压升高,促进肌肉供血,提高肌肉的营养供给,促进肌肉损伤修复。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为本发明所述的组合物干预心身应激模型大鼠肌电变化结果示意图;
图2为本发明所述的组合物干预心身应激模型大鼠肌肉组织的病理切片HE 染色和透射电镜扫描结果示意图;
图3为本发明所述的组合物干预心身应激模型大鼠肌肉血管收缩的结果示意图;
图4为本发明所述的组合物干预心身应激模型大鼠血浆和肌肉中CORT和 ACTH水平的结果示意图。
具体实施方式
下面将结合附图对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
一种抗心因性肌肉震颤的组合物,由如下重量份的原料制成:姜黄1-35份、虎杖1-35、薄荷1-35份、蛇床子1-35份,鹿衔草1-35份、苏木1-35份、降香1-35份、旋复花1-35份、可可脂1-50份。
该组合物可显著抑制心理应激反应引起的神经过度兴奋性,降低静息状态下肌肉的张力、缓解神经和肌肉紧张,达到抑制肌肉震颤的效果;同时还可降低血液中促肾上腺素和肾上腺素皮质酮的水平,降低肌肉兴奋性,抑制肌肉线粒体和内质网的氧化反应,抑制肌肉间质水肿,防止肌肉震颤损伤;并且能促进肌肉组织血管的舒张,改善心理应激引起的血压升高,促进肌肉供血,提高肌肉的营养供给,促进肌肉损伤修复。
作为优选实施例:姜黄12份、虎杖20份、薄荷18份、蛇床子30、鹿衔草 30份、苏木18份、降香18份、旋复花35份、可可脂50份。
制备方法:取配方份的姜黄、虎杖、鹿衔草、旋复花用乙醇回流提取,减压浓缩至2g生药/mL,喷雾干燥;取蛇床子、降香、薄荷,苏木十倍水溶剂下水蒸气蒸馏8小时制备精油;将可可脂在50℃水浴下融化,与精油充分混合,水浴涡旋条件下逐量加入喷雾干燥粉末,冰水浴中静置冷却即得制剂。
实施例中药组抗心因性肌肉震颤实验,制备中药组1g=1mL的提取液,将实验用SD雄性大鼠随机分为空白对照组、模型对照组、组方低剂量组、组方中剂量组、组方高剂量组,除空白对照组外,各组均采用每天束缚12h、噪音声刺激2h、冰水刺激、夹尾疼痛刺激10min,昼夜颠倒的方法持续6周建立慢性应激大鼠模型。在维持模型刺激调节的基础上分别给予各种设计药物,连续用药7d。麻醉大鼠,沿大鼠后腿方向剪开皮肤3cm,剪去筋膜暴露腓肠肌,在腓肠肌远、近端插入电极,经电生理记录仪检测各组模型动物静息期腓肠肌肌电信号。
肌电信号采集结束后,各组大鼠麻醉后脱颈处死,剪取完整的腓肠肌动脉条,置于4℃的HEPES液中,体式显显微解剖镜下分离腓肠肌动脉,剪成长度约为2~3mm动脉血管环,悬挂在血管张力描记仪的张力感应环和张力换能器的电极上,持续通以95%O2-5%CO2混合气。腓肠肌动脉环负荷2mN的基础张力,平衡1h后,分别使用0.01-5μM的去甲肾上腺素收拾血管,计算各组血管收缩的起效剂量。
取部分深层腓肠肌组织,HE染色观察病理学变化,同一位置剪取肌肉组织进行透射电镜扫描,观察肌肉微观结构变化。
酶联免疫吸附测定(ELISA)试剂盒用于确定各组大鼠血浆和肌肉组织中 CORT和ACTH含量。
结果分析:(1)如图1所示,可见对照组在静息状态下腓肠肌肌电信号平稳,活跃度低,几乎无自主收缩。应激模型组在静息状态下腓肠肌肌电信号依然变化显著,肌电信号活跃度高,间隔规则,呈震颤样自主收缩。各组方给药组大鼠在静息状态下腓肠肌肌电信号波动较模型组显著减弱,肌电信号活跃度减少,组方低剂量组和中剂量组有少量自主收缩,高剂量组肌电反应最少,无明显震颤样自主收缩。分析为中药组可降低应激模型肌肉的自主收缩作用,减少和抑制肌肉震颤,随剂量增加作用更显著;
(2)如图2所示,可见应激模型组肌肉间质有显著增生,增生组织中有炎性浸润反应,透射电镜中可观察到肌肉线粒体多数结构不完整,多数线粒体已成空泡样结构,内质网水肿。组方低剂量组肌肉间质有增生结构,增生组织中有炎性浸润反应,透射电镜中可观察到肌肉线粒体部分结构不完整,有部分空泡,内质网有水肿。组方中剂量组肌肉间质有增生结构,增生组织中炎性反应少,透射电镜中可观察到肌肉线粒体少数结构不完整,有部分空泡,内质网水肿不显著。组方高剂量组肌肉间质无显著增生结构,但肌肉间质增加,透射电镜中可观察到肌肉线粒体结构基本完整,线粒体内有少量空泡,内质正常。分析为中药组可降低应激模型肌肉结构损伤,抑制间质增生,减少肌肉线粒体的氧化损伤和内质网水肿,随剂量增加作用更显著;
(3)如图3所示,可见应激模型组肌肉血管对NE的敏感性较对照组显著增加,NE收缩起效剂量显著降低,各给药组肌肉血管的NE收缩起效剂量较模型组显著增加,组方高剂量组增加最显著。分析为中药组可降低应激模型肌肉血管对NE的敏感性,降低NE对肌肉血管的收缩作用,增加肌肉血管的供血效率。
(4)如图4所示,可见应激模型组血浆和肌肉组织中CORT和ACTH水平显著增加,各给药组血浆和肌肉组织中CORT和ACTH水平较模型组显著减少。中药组可显著抑制应激模型的CORT和ACTH水平,降低模型的过度兴奋性。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应所述以权利要求的保护范围为准。

Claims (7)

1.一种抗心因性肌肉震颤的组合物,其特征在于,由如下重量份的原料制成:姜黄1-35份、虎杖1-35、薄荷1-35份、蛇床子1-35份、鹿衔草1-35份、苏木1-35份、降香1-35份、旋复花1-35份、可可脂1-50份。
2.根据权利要求1所述的抗心因性肌肉震颤的组合物,其特征在于:姜黄12份、虎杖20份、薄荷18份、蛇床子30、鹿衔草30份、苏木18份、降香18份、旋复花35份、可可脂50份。
3.根据权利要求1所述的抗心因性肌肉震颤的组合物,其特征在于:用于抑制心理应激反应引起的神经过度兴奋性,降低静息状态下肌肉的张力、缓解神经和肌肉紧张,抑制肌肉震颤。
4.根据权利要求1所述的抗心因性肌肉震颤的组合物,其特征在于:用于降低血液中促肾上腺素和肾上腺素皮质酮的水平,降低肌肉兴奋性,抑制肌肉线粒体和内质网的氧化反应,抑制肌肉间质水肿,防止肌肉震颤损伤。
5.根据权利要求1所述的抗心因性肌肉震颤的组合物,其特征在于:用于促进肌肉组织血管的舒张,改善心理应激引起的血压升高,促进肌肉供血,提高肌肉的营养供给,促进肌肉损伤修复。
6.根据权利要求2所述的抗心因性肌肉震颤的组合物,其特征在于,制备方法包括如下步骤:
步骤S1,取配方份的姜黄、虎杖、鹿衔草、旋复花用乙醇回流提取,减压浓缩至2g生药/mL,喷雾干燥;
步骤S2,蛇床子、降香、薄荷,苏木十倍水溶剂下水蒸气蒸馏8小时制备精油;
步骤S3,将可可脂在50℃水浴下融化,与精油充分混合,水浴涡旋条件下逐量加入喷雾干燥粉末,冰水浴中静置冷却即得制剂。
7.根据权利要求6所述的抗心因性肌肉震颤的组合物,其特征在于,所述步骤S1中的乙醇浓度均为45%。
CN202210091750.9A 2022-01-26 2022-01-26 一种抗心因性肌肉震颤的组合物 Active CN114470133B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210091750.9A CN114470133B (zh) 2022-01-26 2022-01-26 一种抗心因性肌肉震颤的组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210091750.9A CN114470133B (zh) 2022-01-26 2022-01-26 一种抗心因性肌肉震颤的组合物

Publications (2)

Publication Number Publication Date
CN114470133A CN114470133A (zh) 2022-05-13
CN114470133B true CN114470133B (zh) 2022-11-22

Family

ID=81475451

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210091750.9A Active CN114470133B (zh) 2022-01-26 2022-01-26 一种抗心因性肌肉震颤的组合物

Country Status (1)

Country Link
CN (1) CN114470133B (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112535718A (zh) * 2020-12-28 2021-03-23 中国人民解放军总医院第七医学中心 一种治疗心身应激引起肌肉消减萎缩的中药组方

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112535718A (zh) * 2020-12-28 2021-03-23 中国人民解放军总医院第七医学中心 一种治疗心身应激引起肌肉消减萎缩的中药组方

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
两种赋形剂载体中姜黄素干预慢性应激大鼠抑郁样行为和肌肉炎性反应的作用研究;姜维等;《现代生物医学进展》;20210131;第21卷(第2期);209,223-227 *
心因性震颤的研究进展;管昭锐等;《中风与神经疾病杂志》;20161130(第11期);1051-1053 *
震颤的电生理评估;王刚等;《诊断学理论与实践》;20160425(第02期);199-201 *

Also Published As

Publication number Publication date
CN114470133A (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
Akah et al. Evaluation of the anti-asthmatic property of Asystasia gangetica leaf extracts
Kulkarni et al. Withania somnifera: an Indian ginseng
KR101444497B1 (ko) 안드로그라폴라이드를 유효 성분으로 하는 항피로제 및 경구 조성물
BRPI0617988A2 (pt) composição anti-obesidade, uso de extrato de melissa, uso de uma mistura de extrato de melissa e extrato de mori folium, uso de uma mistura de extrato de melissa, extrato de artemisia e extrato de mori folium e método para suprimir a obesidade
EP1763359B1 (en) Use of pregnane glycosides in the treatment/management of obesity
KR101908978B1 (ko) 스트레스 완화 및 피로 회복 효과를 갖는 향료 조성물 및 이를 함유하는 화장료 조성물
KR20200063855A (ko) 밀크씨슬 꽃 추출물을 유효성분으로 포함하는 멜라닌 생성 촉진용 조성물
KR101712790B1 (ko) 필발 추출물을 포함하는 배뇨 장애 예방, 치료 및 개선용 조성물
CN114470133B (zh) 一种抗心因性肌肉震颤的组合物
Katekhaye et al. An inside preview of nutritional and pharmacological profile of Celastrus paniculatus
KR101690175B1 (ko) 고본 추출물을 유효성분으로 포함하는 불면증의 예방 또는 치료용 약학적 조성물
CN107320674A (zh) 一种中药组合物及其应用
KR101321754B1 (ko) 류마티스 관절염 및 골관절염의 개선 또는 치료를 위한 조성물
KR101365794B1 (ko) 숙취해소 및 간 보호기능 개선 조성물
KR20040108512A (ko) 혼합 생약재 추출물 및 이를 유효성분으로 함유하는발기부전 치료용 조성물
Biswas et al. In search of spermatogenetic and virility potential drugs of ayurvedic leads: A review
KR100715939B1 (ko) 마약중독 치료제
Oladele et al. Anti-inflammatory and analgesic effects of aqueous leaf extracts of Gomphrena celosioides and Momordica charantia
RU2546522C2 (ru) Фармацевтическая композиция для лечения зависимости от наркотиков
KR101864425B1 (ko) 황금 추출물을 포함하는 통증 완화 또는 치료제
KR20190016013A (ko) 스트레스 완화용 조성물, 이를 포함하는 기능성 식품 및 약제학적 조성물
KR20040008975A (ko) 뇌기능 및 인지 기능 개선 활성을 갖는 조성물
Appiah et al. Prospects of Croton membranaceus for prostate health
Asije et al. Anticonvulsant activity of Emilia sonchifolia leaf extracts
KR20090023759A (ko) 복합생약 추출물을 함유하는 관절염 치료용 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant